before admission to our Clinic, because of persistent symptoms of high fever (body temperature above 38°C), severe nonproductive cough, nasal secretion, facial swelling, especially around the nose, and erythema on the hands. A diff erential white blood cell count and urinalysis were performed, and except mild eosinophilia of 6% (normal range 0 -5%) all other fi ndings were within normal limits. She was advised to stop taking all drugs. Th e patient was using three drugs (olanzapine: an antipsychotic serotonin blocker; lamotrigine: an antiepileptic and mood stabilizer; and losartan: an antihypertensive and angiotensin II receptor blocker), since she was discharged from the Clinic of Psychiatric Diseases a month before, where she was hospitalized under the diagnosis of paranoid personality disorder. Due to persistent high temperature and worsening of respiratory symptoms, the patient was examined by the specialist for infectious diseases, who set the diagnosis of acute bronchiolitis, and introduced azithromycin 500 mg once daily D rug-induced delayed multiorgan hypersensitivity syndrome (DIDMOHS) (1), also known as drug rash (reaction) with eosinophilia and systemic symptoms (DRESS) syndrome, is a severe, unexpected drug reaction which aff ects several organ systems at the same time (2, 3, 4). Most commonly it causes a combination of high fever, morbiliform skin rash and infl ammation of one or more internal organs including the liver, kidneys, lungs and/or heart. It generally starts two to eight weeks after taking the off ending medicine. Th e drugs most often reported with DRESS include anticonvulsants (particularly those with aromatic structures), sulfa derivatives, antidepressants, non-steroidal anti-infl ammatory drugs, and antimicrobials (5, 6, 7).
before admission to our Clinic, because of persistent symptoms of high fever (body temperature above 38°C), severe nonproductive cough, nasal secretion, facial swelling, especially around the nose, and erythema on the hands. A diff erential white blood cell count and urinalysis were performed, and except mild eosinophilia of 6% (normal range 0 -5%) all other fi ndings were within normal limits. She was advised to stop taking all drugs. Th e patient was using three drugs (olanzapine: an antipsychotic serotonin blocker; lamotrigine: an antiepileptic and mood stabilizer; and losartan: an antihypertensive and angiotensin II receptor blocker), since she was discharged from the Clinic of Psychiatric Diseases a month before, where she was hospitalized under the diagnosis of paranoid personality disorder. Due to persistent high temperature and worsening of respiratory symptoms, the patient was examined by the specialist for infectious diseases, who set the diagnosis of acute bronchiolitis, and introduced azithromycin 500 mg once daily D rug-induced delayed multiorgan hypersensitivity syndrome (DIDMOHS) (1) , also known as drug rash (reaction) with eosinophilia and systemic symptoms (DRESS) syndrome, is a severe, unexpected drug reaction which aff ects several organ systems at the same time (2, 3, 4) . Most commonly it causes a combination of high fever, morbiliform skin rash and infl ammation of one or more internal organs including the liver, kidneys, lungs and/or heart. It generally starts two to eight weeks after taking the off ending medicine. Th e drugs most often reported with DRESS include anticonvulsants (particularly those with aromatic structures), sulfa derivatives, antidepressants, non-steroidal anti-infl ammatory drugs, and antimicrobials (5, 6, 7) . during three days; the chest X-ray was normal and the patient was advised to visit a dermatologist. At the fi rst dermatological examination, the patient had diff use facial fl ushing with mild edema, and morbiliform skin rash mainly on the extremities. In addition to azithromycin, an antihistamine levocetirizine was introduced. In spite of the therapy, the skin rash was spreading, therefore hospitalization was recommended. On admission, the dermatology examination revealed diff use erythematous and slightly edematous face, generalized maculopapular livid erythematous rash partly confl uent on the trunk and extremities involving more than 50% of the body surface (Figures 1, 2) . No peripheral lympadenomegaly was detected. 9 /L or 20 -40%), monocytes -0.9 x10 9 /L or 5.4% (normal range: 0.08 -1x10 9 /L or 2 -10%), eosinophils -2.38x10 9 /L or 13.8% (normal range: 0 -0.5x10 9 /L or 0 -5%), basophils -0. Th e diagnosis of DRESS syndrome was established based on the diagnostic criteria for DRESS syndrome, including skin rash, blood count and laboratory abnormalites that were as follows: leukocytosis (>11x109/L), eosinophilia (>1.5x109/L), atypical lymphocytes (>5%) and liver abnormalities (ALT>100 IU/L) (6, 8) . During the seven-day hospital stay, the patient received 40 mg methylprednisolone daily, a systemic steroid, and oral ranitidine, loratadine; -an antihistaminic, butamirate citrate -an antitussic, and losartan -an antihypertensive. After being discharged, the patient continued oral corticosteroid therapy with 40 mg prednisolone daily, with dose reduction by 10 mg after every seven days. She continued taking ranitidine and losartan. On discharge, she still presented with erythematous macular rush. Th ree weeks later, laboratory fi ndings (WBC with diff erential count, RBC, AST, ALT, urinanalysis and serum amylase) normalized, but the pale residual pinkish macular skin rash was still persistent (Figures  3 -6 ). On last visit, six weeks after hospitalization and 8 weeks after lamotrigne and olanzapine were discontinued, the skin lesions completely resolved. Due to the psychiatrist's recommendation, olanzapine was reintroduced into the therapy, and since then the patient has been taking it without any problems.
Laboratory and other relevant fi ndings

Discussion
Before 1996, when Bouquet and associates described the DRESS syndrome, several diff erent terms have been used such as: anticonvulsant hypersensitivity syndrome, fi rst described in 1936 during the treatment with anticonvulsant drugs; drug hypersensitivity syndrome; drug-induced hypersensitivity syndrome (9, 10, 11) . Th e "R" was previously used to indicate "rash" (9), now it indicates "reaction" (3).
Th ough DRESS syndrome was recognized as a serious form of skin drug adverse reaction from the very beginning, it is currently viewed as a drug-related syndrome with life-threatening organ dysfunctions. A long interval from fi rst drug exposure to symptom onset and a prolonged course after discontinuation of the off ending drug even with fl ares, represent the two highly typical features of the syndrome (12) . Th e syndrome is also characterized by an extensive rash, fever, lymphadenopathy, hematologic abnormalities, hepatitis, and involvement of the kidneys, lungs, heart, or pancreas. Although skin lesions may rapidly aggravate from erythematous to purpuric, pustrular or turn to exfoliative dermatitis, they can be overshadowed by the severity of organ involvement, hence "reaction" instead of "rash" in the acronym DRESS (13) . Th e onset of symptoms is often delayed, occurring 2 -8 weeks after drug initiation (14) . In our patient symptoms occurred one month after initiation of three drugs, two of which being psychoactive (olanzapine -antipsychotic serotonin blocker; lamotrigine -antiepileptic and mood stabilizers; and losartan -antihypertensive and angiotensin II receptor blockers).
Th e incidence of DRESS has been estimated to be between 1 in 1,000 and 1 in 10,000 drug exposures. It carries a mortality rate of 10 -20%, with most fatalities due to liver failure (15) .
Th e exact pathogenesis of DRESS syndrome is not yet well understood. Although it is considered an idiosyncratic reaction, three potential causative factors have been identifi ed among multiple cases: 1) a defect in drug metabolism resulting in the failure to eliminate toxic reactive intermediates (e.g. slow acetylation and defects in enzymes responsible for drug metabolism such as arene oxidase for anticonvulsants); 2) reactivation of human herpes virus-6 (HHV-6), human herpes virus-7 (HHV-7), Epstein-Barr virus (EBV), or cytomegalovirus (CMV), which may act as a trigger for the immune reaction; 3) or genetic predisposition that alters immune response (4, 16, 17) .
Two groups have developed specifi c criteria for making the diagnosis of DRESS syndrome: Th e European Registry of Severe Cutaneous Adverse Reactions Group (Th e RegiSCAR group) and Japanese Consensus Group (SCAR-J). Th e RegiSCAR study group developed a set of inclusion criteria (Table 1) and established a scoring system (total score ranges from 4 to 9), for classifying DRESS cases as defi nitive with fi nal score >5, probable with fi nal score 4 -5, possible with fi nal score 2 -3, and no case with fi nal score <2 (8) .
According to RegiSCAR group criteria, our patient met all criteria except lymphadenopathy and reduced platelets. According to the RegiSCAR group scoring system, eosinophilia (>1.5x109/L), atypical lymphocytes (>5%), skin involvement (>50%), suggestive skin rash, and liver abnormalities (ALT>100 IU/L) were scored as 2+1,+1,+1, and +1, respectively (8) . Since the fi nal score was +6, the diagnosis of DRESS syndrome was defi nite in our patient.
According to the Japanese Consensus Group criteria for DRESS syndrome, our patient fulfi lled the fi rst fi ve, thus being classifi ed as having atypical DRESS syndrome (Table 2) (6). In comparison to criteria developed by the RegiSCAR group, the major diff erence was inclusion of HHV-6 reactivation (6). However, the use of HHV-6 reactivation as a criterion is controversial, because no defi nite evidence of the causative role of herpes viruses in DRESS syndrome has been reported (18) . In the in vitro studies, it was found that drugs associated with DRESS syndrome do not only potentiate HHV-6 and EBV replication by inhibition of epigenetic control mechanisms (the two main are methylation and histone acetylation), but also induce an antiviral T-cell immune response in individuals with genetic susceptibility factors, by interacting with the major histocompatibility complex receptor (12) . Since anticonvulsant drugs can induce hypogammaglobulinemia, it has been hypothesized that use of drugs associated with DRESS syndrome may promote viral reactivation by inducing immunosuppression. However, the mechanism underlying the direct drug-virus interaction remains unknown. Only a minority of transplant recipients with marked viral reactivation develop systemic manifestations. Th e systemic manifestations are suggested to be related to a strong immune response against the reactivated virus. Th us, DRESS syndrome, develops only in patients with both marked viral reactivation and an ability to produce a strong antiviral immune response (e.g. genetic polymorphisms for cytokines, receptors, or antagonists (as demonstrated for the TNF-receptor) (12) . Meanwhile, Japanese criteria are less practical in routine clinical practice, as viral serologic tests are unhelpful (18) . Quantitative PCR of the whole blood must be used in order to detect viral reactivations (12) .
Th e liver is the most commonly involved organ in DRESS syndrome, and hepatitits, present also in our patient, occurs in about 80% of all cases (19, 20, 21) . Th e degree of hepatitis is related to the interval between the onset of the syndrome and the discontinuation of the off ending drug. Apart from the liver, another, most frequently aff ected organs are the kidneys in 40% and lungs in 33% of cases. Cardiovascular symptoms develop in 15% of cases, and pancreas is involved in about 5% of cases (22) . Th e most common hematologic disorders that occur in DRESS syndrome are as follows: atypical lymphocytes (63%), eosinophilia (52%), lymphocytopenia (45%), and thrombocytopenia (25%) (23, 24) . Our patient had leukocytosis (>11x10 9 /L), eosinophilia (>1.5 x 10 9 ) and atypical lymphocytosis (>5%). Th e outcome is usually favorable after discontinuation of the casual drug, although full symptom resolution requires at least two weeks and fl ares may occur. Moreover, after prompt withdrawal of the off ending agent, complete resolution of skin lesions and visceral injury can be achieved in up to several weeks, which happened after 8 weeks in our patient. Although in less severe cases resolution can be achieved by using only supportive measures, in cases with internal organ impairment, moderate to high doses of corticosteroids should be commenced, but not before infection has been carefully ruled out! Corticosteroids should be gradually tapered over a period of 6 -8 weeks as in our patient, in order to prevent relapse which may occur especially with rapid discontinuation. Time to onset is shorter after rechallenge with the same drug.
Th ere are more than 40 drugs, including lamotrigine and olanzapine, that have been reported to be associated with DRESS syndrome (18) . Aromatic anticonvulsants (phenytoin, phenobarbital, carbamazepine) and sulphonamides are the most common causative drugs, but a variety (18, (20) (21) (22) (23) (24) (25) (26) (27) . Lamotrigine [6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine] is an antiepileptic drug, used in the management of a broad range of seizures in adults and children which is not an aromatic antiepileptic, thus being structurally and pharmacologically unrelated to other antiepileptic medications e.g. carbamazepine (28, 29) . Lamotrigine has been repoted in association with severe skin rash, multiorgan failure, DRESS syndrome, acute hepatic failure, and disseminated intravascular coagulation. Severe rashes due to lamotrigine occurr almost regularly within the fi rst 6 -8 weeks of exposure, rarely after 12 weeks and almost exclusively later (30) . Several reports of lamotrigine-induced DRESS syndrome have been reported in the literature (12, 27, 28, 29, (31) (32) (33) (34) . Th e second psychoactive drug our patient was taking in combination with lamotrigine was an antipsychotic -olanzapine, an oxazepine that is prescribed to patients with schizophrenia or recurrent bipolar disorder. Regarding cutaneous adverse drug reactions due to olanzapine, the literature contains few reports of DRESS syndrome, contrary to lamotrigine that has commonly been reported as a causative agent in DRESS syndrome. Actually, in a frequently cited review on DRESS syndrome published in 2011 by Cacoub et al, only one case involved olanzapine (35) . Since then, according to available literature, there are four new published cases of DRESS syndrome associated with olanzapine (12, (36) (37) (38) . Although drug-drug interactions have been reported between antiepileptic and antipsychotic drugs, there was only one report of cross-sensitization between carbamazepine (aromatic antiepileptic drug) and olanzapine (aromatic antipsychotic drug) (38) .
Th e diagnosis of DRESS syndrome in our case was defi nite. However, regarding causality, due to the scoring system established by Naranjo et al, it was a probable adverse drug reaction caused by lamotrigine (fi nal score 7); we did not confi rm the adverse event by at least one objective evidence e.g. by skin testing (39) . Skin tests can assist in the causality assessment, but performed at a time distance from the DRESS Table 2 . Japanese group's criteria for diagnosis* ** of DRESS syndrome Human herpes virus-6 reactivation *Th e diagnosis of typical syndrome is confi rmed by the presence of all 7 criteria **Th e diagnosis of atypical syndrome is confi rmed by the presence of the fi rst 5 criteria syndrome episode (12) . Given the fact that lamotrigine, opposed to olanzapine, is known as a common cause of DRESS syndrome, that there is no cross reactivity between them, and there was a necessity of its use in the given moment, the psychiatrist considered that olanzapine should be reintroduced into the therapy. If the psychiatrist had not reintroduced olanzapine into the therapy, patch testing would be performed in 6 months, and olanzapine would gradually be reintroduced under hospital supervision. Th erefore, now we can only hypothesize that lamotrigine was directly responsible for our patient's rash, and all other symptoms and signs.
Conclusion
We present a case of a female patient who was treated with an antipsychotic -olanzapine in combination with an anticonvulsant -lamotrigine. Since both drugs were discontinued due to the development of DRESS syndrome, and with regard to the chronology of events, lamotrigine was considered the main suspected drug.
Abbreviations
DRESS -drug rash (reaction) with eosinophilia and systemic symptoms DIDMOHS -drug-induced delayed multiorgan hypersensitivity syndrome ESR -erythrocyte sedimentation rate CRP -C-reactive protein WBC -white blood cell count RBC -red blood cell count PLT -platelets AST -aspartate aminotransferase ALT -alanine aminotransferase ELISA -enzyme-linked immunosorbent assay HSV -herpes simplex virus Ig -immunoglobulins EBV -Epstein-Barr virus CMV -cytomegalovirus RegiSCAR -Registry of Severe Cutaneous Adverse Reactions SCAR-J -Japanese Consensus Group. HHV -human herpesvirus TNF -tumor necrosis factor PCR -polymerase chain reaction
Lamotrigin udružen sa DRESS sindromom -prikaz slučaja
Sažetak
Uvod. Lekom izazvan odložen multiorganski sindrom poznat i pod nazivom DRESS (eng. drug reaction with eosinophilia and systemic symptoms), podrazumeva neočekivanu lekom izazvanu reakciju koja se klinički najčešće manifestuje visokom temperaturom, morbiliformnim osipom na koži i upalom jednog ili više unutrašnjih organa, uključujući jetru, bubrege i/ili srce, dve do osam nedelja nakon uključivanja leka u terapiju. Lekovi koji najčešće izazivaju ovaj sindrom su: aromatski antikonvulzanti, sulfaderivati, antidepresanti, nesteroidni antiinfl amatorni i antimikrobni agensi. Prikaz slučaja. Prikazujemo slučaj četrdeset-četvorogodišnje ženske osobe koja od puberteta ima psihijatrijske tegobe. Sedam dana pre prijema na našu kliniku, javila se u Urgentni centar zbog visoke febrilnosti, intenzivnog neproduktivnog kašlja, nazalne sekrecije, otoka i crvenila lica i šaka. Rutinska laboratorijska ispitivanja ukazala su na blagu eozinofi liju od 6% (referalne vrednosti 0−5%). uzroka: 1) defekt u metabolisanju leka koji rezultira neadekvatnom eliminacijom toksičnih reaktivnih intermedijarnih produkata (npr. usporena acetilacija ili poremećana aktivnost arena oksidaze, enzima odgovornog za metabolisanje antikonvulzivnih lekova; 2) reaktivacija humanog herpes virusa-6 (HHV-6), humanog herpes virusa-7 (HHV-7), Epštajn-Barovog virusa (EBV), ili citomegalovirusa (CMV), koja može da pokrene reakciju imunskog sistema; 3) genetska predispozicija za poremećan imunski odgovor. Evropska, RegiSCAR grupa istraživača (engl. Th e European Registry of Severe Cutaneous Adverse Reactions Group) i Japanska konsenzus grupa (eng. Th e Japanese Consensus Group), utvrdile su dijagnostičke kriterijume za DRESS sindrom: Inkluzioni kriterijumi koje je uspostavila RegiSCAR groupa izneti su u Tabeli 1 i oni služe za postavljanje dijagnoze DRESS sindroma, dok se na osnovu skoring sistema (ukupni skor se kreće od -4 do +9), vrši klasifi kacija dijagnoze DRESS sindroma na defi nitivnu (ukupnii skor > 5), verovatnu (ukupni skor 4-5), moguću (ukupni skor 2-3), ili se dijagnoza isključuje (ukupni skor < 2). Prema RegiSCAR kriterijumima, kod naše pacijentkinje su osim trombocitopenije i limfadenopatije bili prisutni svi ostali kriterijumi, koji su skorovani: eozinofi lija (> 1,5 x 10 9 /L) sa +2 atipični limfociti (> 5%) sa +1, procentualna zahvaćenost kože (> 50%) sa +1, osip koji ne isključuje dijagnozu DRESS sindroma sa +1, poremećaj fi nkcije jetre (ALT > 100 IU/L) sa +1. S obzirom da je ukupni skor koda naše pacijentkinje iznosio +6, dijagnoza DRESS sindroma kod naše pacijentkinje je bila defnitivna. Prema kriterijumima Japanske konsenzus grupe za postavljanje dijagnoze DRESS sindroma, naša pacijentkinja je imala pet prvih od ukupno sedam kriterijuma, što je odgovaralo dijagnozi atipičnog DRESS sindroma (Tabela 2). U odnosu na kriterijume koje je dala RegiSCAR grupa, glavna razlika je što je u kriterijume Japanske konsenzus grupe uključena i reaktivacija infekcije sa HHV-6, što je u nedostatku dokaza o direktnoj ulozi herpes virusa u nastanku DRESS sindroma izazvalo kontroverzne stavove. U in vitro istraživanjima utvrđeno je da lek udružen sa pojavom DRESS sindroma, ne samo da pospešuje replikaciju HHV-6 i EBV virusa putem inhibicije epigenetskih kontrolnih mehanizama (dva glavna mehanizma su metilacija i histonska acetilacija), nego kod genetski predisponiranih osoba (npr. genetski polimofi zam za citokine, receptore ili antagoniste, kao što je pokazano za TNF-receptor), pokreće i antivirusni T-ćelijski imunski odgovor putem interakcije sa receptorima glavnog histokompatibilnog kompleksa. Japanski kriterijumi su se istovremeno pokazali manje praktičnm, s obzirom na mali dijagnostički značaj seroloških testova i potrebe za uključivanjem kvantitativne PCR u krvi, sa ciljem detekcije reaktivacije virusa. Jetra je najćešće zahvaćen organ, a hepatitis, prisutan i kod naše pacijentkinje, može se javiti u preko 80% slučajeva, potom sledi zahvaćenost bubrega u 40%, pluća u 33%, kardiovaskularnog sistema u 15% i pankreasa kao kod naše pacijentkinje u 5% slučajeva. Najčešće opisani hematološki poremaćaji u DRESS sindromu su: povećan broj atipičnih limfocita (63%), eozinofi lija (52%), limfocitopenija (45%), i trombocitopenija (25%). Kod naše pacijentkinje bila je prisutna: leukocitoza (> 11 x 109/L), eozinofi lija (> 1,5 x 10 9 ) i povišen broj atipičnih limfocita (> 5%). Prognoza je je dobra ukoliko se na vreme isključi inkriminisani lek, iako je za postizanje kompletne remisije potrebno nekoliko nedelja, kao kod naše pacijentkinje, gde je do kompletne rezolucije bilo potrebno 8 nedelja. Ukoliko su jače zahvaćeni unutrašnji organi, potrebno je u terapiju uključiti sistemske kortikosteroide u srednjim i visokim dozama, ali je potrebno prethodno isključiti postojanje infekcije. Ukoliko se pažljivo, tokom 6−8 nedelja smanjuje doza kortikosteroida, snižava se rizik od recidiva, što smo i mi sproveli kod naše pacijentkinje. Ukoliko se u terapiju ponovo uvede inkriminisani lek, simptomi se javljaju posle kraćeg vremenskog perioda od uključivanja leka. Preko 40 različitih lekova među kojima su i lamotrigin i olazapin su u literaturi povezani sa razvojem DRESS sindroma, najčešće su to aromatski antikonvulzivi (fenitoin, fenobarbital, karbamazepin) i sulfonamidi, a potom slede i ostali kao što su dapson (DDS, 4,4-diaminodifenilsulfon), alopurinol, kaptopril, blokatori kallcijumovih kanala, ranitidin, talidomid, minociklin, nesteroidni antiinfl amatorni lekovi, antituberkulotici, -metildopa i antiretrovirusni lekovi (abakavir, zalcitabin, nevirapin). Lamotrigin [6-(2,3-diklorofenil)-1,2,4-triazine-3,5-diamine] nearomatski je antiepilektik, koji ne pokazuje ni
